Rodin Therapeutics

Cambridge, United States Founded: 2013 • Age: 13 yrs Acquired By Alkermes
Epigenetic modulators are developed for CNS disorder treatments.
Annual revenue - Latest available
Total funding $57.2M 5 rounds
Employees 13 Tracked headcount
Investors 9 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Rodin Therapeutics

Rodin Therapeutics is a company based in Cambridge (United States) founded in 2013 was acquired by Alkermes in November 2019. Rodin Therapeutics has raised $57.2 million across 5 funding rounds from investors including Biogen, Alkermes and HHS. The company has 13 employees as of December 31, 2022. Rodin Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.

  • Headquarter Cambridge, United States
  • Employees 13 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Rodin Therapeutics, Inc
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $57.2 M (USD)

    in 5 rounds

  • Latest Funding Round
    $27 M (USD), Series C

    Sep 14, 2017

  • Investors
    Biogen

    & 8 more

  • Employee Count
    13

    as on Dec 31, 2022

  • Acquired by
    Alkermes

    (Nov 18, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Rodin Therapeutics

Rodin Therapeutics has successfully raised a total of $57.2M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $27 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Rodin Therapeutics

Rodin Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, Alkermes and HHS.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm investing in life science and biotechnology sectors
Locked Locked Locked
Corporate backed venture capital fund investing in multiple sectors
Locked Locked Locked
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe
Locked Locked Locked
Premium access

Investor details for Rodin Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Rodin Therapeutics

Investments
Premium access

Investment portfolio details for Rodin Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Rodin Therapeutics

Premium access

Detailed financials for Rodin Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Rodin Therapeutics Comparisons

Rodin Therapeutics Primary company
Description
Epigenetic modulators are developed for CNS disorder treatme...
Location
Cambridge, United States
Founded Year
2013
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
13
As of 2022
Premium access

Peer comparison for Rodin Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Rodin Therapeutics

Rodin Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Therapies for neurodegenerative and immunology disorders are developed.
Locked Locked Locked
Developer of small molecule therapeutics for endocrine and CNS disorders
Locked Locked Locked
Small molecule drugs for rare diseases are developed.
Locked Locked Locked
Therapies for neurological and neuropsychiatric diseases are developed.
Locked Locked Locked
Gene and protein therapies are developed for treating various diseases.
Premium access

Detailed competitors of Rodin Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Rodin Therapeutics

Premium access

Complete news archive for Rodin Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rodin Therapeutics

Rodin Therapeutics was founded in 2013.

Rodin Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Rodin Therapeutics is a funded company, having raised a total of $57.2M across 5 funding rounds to date.

As of Dec 31, 2022, the latest employee count at Rodin Therapeutics is 13.

Rodin Therapeutics was founded in 2013 and is headquartered in Cambridge, United States. Focus is placed on the biotechnology sector, where epigenetic modulators are developed for addressing central nervous system disorders. Epigenetic regulation is achieved through HDAC complex modulation, by which synaptic function, neuronal health, and survival are restored in degenerative brain diseases. Operations center on research and therapeutic development in this field.

Rodin Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.

Rodin Therapeutics has 9 investors. Key investors include Biogen, Alkermes, HHS, Atlas Venture, and Google Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available